- Home
- SABS vs NTIP Comparison
SABS vs NTIP Comparison
Compare SABS & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- NTIP
- Stock Information
- Founded
- SABS 2014
- NTIP 1990
- Country
- SABS United States
- NTIP United States
- Employees
- SABS N/A
- NTIP N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- SABS Health Care
- NTIP Miscellaneous
- Exchange
- SABS Nasdaq
- NTIP Nasdaq
- Market Cap
- SABS 31.2M
- NTIP 32.0M
- IPO Year
- SABS N/A
- NTIP 1998
- Fundamental
- Price
- SABS $4.09
- NTIP $1.49
- Analyst Decision
- SABS Strong Buy
- NTIP
- Analyst Count
- SABS 3
- NTIP 0
- Target Price
- SABS $9.00
- NTIP N/A
- AVG Volume (30 Days)
- SABS 203.1K
- NTIP 5.7K
- Earning Date
- SABS 11-13-2025
- NTIP 11-06-2025
- Dividend Yield
- SABS N/A
- NTIP 6.90%
- EPS Growth
- SABS N/A
- NTIP N/A
- EPS
- SABS N/A
- NTIP N/A
- Revenue
- SABS $114,698.00
- NTIP $150,000.00
- Revenue This Year
- SABS N/A
- NTIP N/A
- Revenue Next Year
- SABS N/A
- NTIP N/A
- P/E Ratio
- SABS N/A
- NTIP N/A
- Revenue Growth
- SABS N/A
- NTIP N/A
- 52 Week Low
- SABS $1.00
- NTIP $1.16
- 52 Week High
- SABS $6.60
- NTIP $1.90
- Technical
- Relative Strength Index (RSI)
- SABS 71.11
- NTIP 48.18
- Support Level
- SABS $3.68
- NTIP $1.30
- Resistance Level
- SABS $4.15
- NTIP $1.48
- Average True Range (ATR)
- SABS 0.31
- NTIP 0.06
- MACD
- SABS 0.04
- NTIP -0.01
- Stochastic Oscillator
- SABS 93.18
- NTIP 65.22
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.